Search adipotide benefits and you get a short list: fat loss, better insulin sensitivity, fat targeted by location. Every item on that list was measured in animals. The one human trial enrolled four people and stopped.
The short answer. Every published adipotide benefit was measured in mice or monkeys, not people.
- The ~11% weight loss figure comes from Barnhart et al., 2011, in obese rhesus monkeys given 0.43 mg/kg for 28 days.
- The insulin sensitivity claim is from the same animals in the same experiment, not a second study.
- The human Phase I trial, NCT01262664, enrolled four people, was terminated, and posted no results.
Adipotide has no proven benefit in people. The weight loss number comes from monkeys. A 2011 study saw about 11% loss in 28 days. Insulin resistance improved in those same animals. The human trial enrolled four people and ended. Kidney injury appeared in the animal data.
Where each adipotide benefit comes from
The claims are not invented. They are lifted from two real papers, and both are animal papers. The problem is the species, not the science.
| Claim | Source | Species | Human evidence |
|---|---|---|---|
| Around 11% body weight lost | Barnhart et al., Science Translational Medicine, 2011 | Obese rhesus monkeys | None |
| Improved insulin resistance | Barnhart et al., 2011 | Obese rhesus monkeys | None |
| Fat removed, not shrunk | Kolonin et al., Nature Medicine, 2004 | Obese mice | None |
| Works without dieting | Both animal papers | Monkeys and mice | None |
| Safe at the doses sold | Nothing | — | None |
The last row is the one to sit with. There is no published human safety dataset for adipotide at any dose. The adipotide complete guide covers how the compound was built at MD Anderson.
Does adipotide cause weight loss?
In monkeys, yes. That result is solid and it is why this compound still has a market Fifteen years later.
Barnhart and colleagues gave obese rhesus monkeys 0.43 mg/kg under the skin, once daily, for 28 days. Ten treated animals lost between 7.4% to 14.7% of body weight. The mean sits around 11%.
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.
Title of Barnhart et al., Science Translational Medicine, 2011The title is the whole claim, and it ends at the word monkeys. Nothing in the paper was measured in a person. The adipotide dosage page lists what each study actually administered.
The insulin benefit is from the same ten animals
The second claim on most product pages is metabolic: better insulin sensitivity, better glucose handling. It comes from the same 2011 paper, the same monkeys, the same 28 days.
So it is not a separate line of evidence. It is one finding from one experiment, counted twice.
Two benefits from one small animal study is still one animal study. If the weight loss result does not transfer to humans, neither does the insulin result, because they were measured in the same bodies at the same time.
- No human glucose data. No HbA1c, no clamp study, no fasting insulin in people.
- No long-term data. The longest published dosing period is 28 days.
- No comparison arm against a drug. Adipotide has never been measured head to head with anything.
Does adipotide target belly fat?
The targeting claim is the oldest one and it traces to Kolonin and colleagues in Nature Medicine, 2004.
Reversal of obesity by targeted ablation of adipose tissue.
Title of Kolonin et al., Nature Medicine, 2004Read the word ablation. The peptide homes to blood vessels feeding white fat and triggers cell death there. The fat tissue loses its blood supply. This is a cytotoxic mechanism, not a metabolic one.
That is a real difference from how fat-loss drugs usually work, and it is also why the compound did not continue down the obesity path. Killing tissue is harder to dose safely than changing appetite signals.
The homing idea did survive in other labs. Hu and colleagues used targeted molecular MRI to measure brown fat activity in a 2021 Magnetic Resonance Imaging paper. Hong and Kim built fat and liver dual-targeting nanoparticles in Advanced Science in 2022. Both are tool and delivery work. Neither is an adipotide benefit.
What happened when adipotide reached humans
There was one registered human trial. It is listed as NCT01262664, a first-in-man Phase I study in patients with metastatic prostate cancer and obesity.
It opened at 0.03 mg/kg, a small fraction of the monkey dose. It enrolled four people.
Terminated; no results posted.
ClinicalTrials.gov record for NCT01262664No results posted means exactly that. There is no published efficacy figure, no safety table, no pharmacokinetic curve from that trial. Obesity development has not moved since.
Every benefit sold under this name was generated before the human trial opened, and the human trial never reported anything that would confirm or refute it.
The kidney signal the benefit lists leave out
The 2011 monkey paper is also where the main safety finding lives. Creatinine rose in treated animals, and the effect was dose related. The paper reported renal changes above 0.25 mg/kg.
Creatinine is a kidney marker. A rise means the kidney is filtering less well. In a study that only ran 28 days, that is an early signal, not a settled question.
- The signal is from the same paper as the benefit. You cannot cite one and skip the other.
- No human renal data exists. The trial that would have produced it was terminated.
- Nothing establishes a safe range in people. Research vials carry no such finding behind them.
If you are evaluating vendor paperwork for anything in this category, how to read a certificate of analysis is the starting point, and the legality page covers research-use status.
How 11% compares to drugs with human trials
The monkey figure sounds large on its own. Against compounds that completed human programs, it is not.
| Compound | Study | Population | Weight change |
|---|---|---|---|
| Tirzepatide | Phase III SURMOUNT-1 | Humans | 22.5% |
| Retatrutide | Phase 2 | Humans | 24.2% |
| Adipotide | 2011 preclinical study | Rhesus monkeys | ~11% |
| Adipotide | Phase I NCT01262664 | Humans | No results posted |
The incretins reached 22–24% in people, with Phase III safety programs attached. This is reported here as trial fact, not as a suggestion. Adipotide reached ~11% in ten monkeys and stopped.
For how this site evaluates sellers and documentation in general, see the buying guide.
What to know now
- Every published adipotide benefit was measured in mice or monkeys, not people.
- The ~11% weight loss figure comes from Barnhart et al., 2011, in obese rhesus monkeys given 0.43 mg/kg for 28 days.
- The insulin sensitivity claim is from the same animals in the same experiment, not a second study.
- The human Phase I trial, NCT01262664, enrolled four people, was terminated, and posted no results.
- The same monkey paper reported rising creatinine, a kidney signal, above 0.25 mg/kg.
- The mechanism is cytotoxic tissue ablation, which is why development stopped rather than scaled.
What we're watching
The single thing that would change this page is a registered human trial with results posted. Fifteen years after the monkey paper, there is none, and no obesity program is running.
Frequently asked questions
Does adipotide actually burn fat?
In obese rhesus monkeys, it caused weight loss of 7.4% to 14.7% over 28 days in the 2011 Science Translational Medicine study. In humans, nothing has been shown. The only human trial enrolled four people and posted no results.
Has adipotide been tested in humans?
Once. ClinicalTrials.gov lists NCT01262664, a Phase I study in patients with metastatic prostate cancer and obesity. It was terminated with four participants enrolled and no results posted.
Is adipotide approved by the FDA?
No. It is not an approved drug anywhere. It is a research compound with no completed human efficacy or safety dataset, and no obesity development program since the Phase I trial ended.
Does adipotide reduce fat in specific areas?
That idea comes from Kolonin et al., Nature Medicine, 2004, where the peptide homed to the blood vessels supplying white fat in mice and triggered cell death there. It has never been demonstrated in people.
What side effects showed up in the research?
The 2011 monkey study reported dose-related rises in creatinine, a marker of reduced kidney filtration, above 0.25 mg/kg. There is no human safety data to compare it against.
Why is adipotide still sold if the trial stopped?
The animal results are genuinely striking, and the compound was built at a major cancer center, so it carries scientific credibility. That credibility belongs to the 2004 and 2011 preclinical papers, not to any human outcome.
References
- Barnhart, K. F., Christianson, D. R., Hanley, P. W., Driessen, W. H. P., Bernacky, B. J., Baze, W. B., Wen, S., Tian, M., Ma, J., Kolonin, M. G., Saha, P. K., Do, K.-A., Hulvat, J. F., Gelovani, J. G., Chan, L., Arap, W., & Pasqualini, R. (2011). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine, 3(108), 108ra112. https://doi.org/10.1126/scitranslmed.3002621
- Kolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., & Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine, 10(6), 625–632. https://doi.org/10.1038/nm1048
- ClinicalTrials.gov. A first-in-man, phase I evaluation of a single cycle of prohibitin targeting peptide 1 in patients with metastatic prostate cancer and obesity (NCT01262664). Terminated; no results posted. https://clinicaltrials.gov/study/NCT01262664
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- Hu, Q., Cao, H., Zhou, L., et al. (2021). Measurement of BAT activity by targeted molecular magnetic resonance imaging. Magnetic Resonance Imaging, 77, 1–6. https://doi.org/10.1016/j.mri.2020.12.006
- Hong, J., & Kim, Y. H. (2022). Fatty liver/adipose tissue dual-targeting nanoparticles with heme oxygenase-1 inducer for amelioration of obesity, obesity-induced type 2 diabetes, and steatohepatitis. Advanced Science, 9(33), e2203286. https://doi.org/10.1002/advs.202203286